The Library
Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans
Tools
Tools
Tools
Tan, Bee K., Chen, Jing, Hu, J., Amar, Omar, Mattu, Harman, Ramanjaneya, Manjunath, Patel, Vanlata H., Lehnert, Hendrik and Randeva, Harpal S. (2014) Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans. Clinical Endocrinology, 81 (6). pp. 841-846. doi:10.1111/cen.12438
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1111/cen.12438
Abstract
OBJECTIVE:
Adipolin/CTRP12 is a novel adipokine with anti-inflammatory and glucose-lowering properties in rodents. We sought to investigate the effects of metformin treatment (850 mg twice daily for 6 months) and a 2 h 75 g oral glucose tolerance test (OGTT) on serum adipolin concentrations in humans.
DESIGN:
Cross-sectional study [PCOS (n = 83) and control (n = 39) subjects]. Serum adipolin was measured by ELISA. Metformin treatment (850 mg twice daily for 6 months) was offered to all women with PCOS, 34 women participated but 21 women completed 6 months of metformin therapy. Reasons for subjects not completing the study were nausea and gastrointestinal side effects (n = 4), pregnancies (n = 5), noncompliance (n = 2) and loss of contact (n = 2).
RESULTS:
Metformin treatment (850 mg twice daily for 6 months) substantially increased serum adipolin concentrations (P < 0·05) in women with polycystic ovary syndrome (PCOS), a pro-inflammatory state associated with obesity, diabetes, dyslipidaemia and atherosclerosis. Furthermore, changes in waist-hip ratio, glucose, triglycerides, CRP and carotid intima media thickness showed significant negative associations with changes in adipolin levels (P < 0·05, P < 0·01); in multiple regression analyses, only changes in glucose were predictive of changes in adipolin levels (β = -0·570, P = 0·009). Serum adipolin decreased significantly in response to the OGTT in PCOS and control subjects at 90 min (P < 0·05) and 120 min (P < 0·01).
CONCLUSIONS:
Adipolin and/or novel pharmacologic agents that increase adipolin's circulating concentrations might constitute a novel approach in the treatment of insulin resistant states.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Divisions: | Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) | ||||
| Journal or Publication Title: | Clinical Endocrinology | ||||
| Publisher: | Wiley-Blackwell Publishing Ltd | ||||
| ISSN: | 0300-0664 | ||||
| Official Date: | 8 December 2014 | ||||
| Dates: |
|
||||
| Volume: | 81 | ||||
| Number: | 6 | ||||
| Page Range: | pp. 841-846 | ||||
| DOI: | 10.1111/cen.12438 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Open Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
